AccessibilityHelpAbout Us
Spectral Medical logo

Spectral Medical(OTC) EDTXF

Market Cap$267.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-85%
5 Year+250%
1 Year-27%
1 Month-9%
$0.91
-1.05%
-0.01Today
Spectral Medical last closing stock price
MetricPriceDate
Last closeUSD 0.912026-09-10
Spectral Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.62%USD 0.902026-09-03
1 month-9.42%USD 1.012026-08-11
3 month-7.49%USD 0.982026-06-12
Year to date-12.47%USD 1.042025-12-31
1 year-26.59%USD 1.242025-09-10
3 year+199.45%USD 0.302023-09-07
5 year+250.13%USD 0.262021-09-10
Since inception-84.83%USD 6.001992-07-16

Spectral Medical Financials at a Glance

Market Cap

$267.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$2.57M

Net Income (TTM)

-CA$35.77M

EPS (TTM)

-$0.09

P/E Ratio

-10.09

Dividend

$0.00

Beta (Volatility)

0.03 (Low)

Price

$0.91

Volume

7,383

Open

$0.90

Previous Close

$0.91

Daily Range

$0.90 - $0.91

52-Week Range

$0.81 - $1.24

Estimated Earnings Date

Nov 6, 2026

EDTXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Spectral Medical

Spectral Medical Inc. is a healthcare company focused on developing and commercializing innovative products for the treatment of septic shock. The company operates internationally, offering diagnostic and therapeutic solutions aimed at improving patient outcomes in critical care settings.

Products and Services
  • Endotoxin Activity Assay for rapid detection of gram-negative bacterial components
  • Polymyxin B-Hemoperfusion device for endotoxin removal from the bloodstream
  • Monoclonal and polyclonal antibodies for research and development purposes
Growth Outlook
  • Recent quarterly revenue increased to CAD 621,000, showing potential for growth
  • Expansion into international markets enhances revenue opportunities
  • Focus on innovative therapies positions the company for future advancements
Financial Highlights
  • Trailing twelve months (TTM) revenue of CAD 2.5 million indicates market interest
  • Net income for the latest quarter improved to CAD 331,000
  • Cash and cash equivalents at CAD 803,000 provide operational liquidity
Spectral Medical Inc. is strategically positioned in the medical diagnostics and research sector, focusing on critical care solutions. The company's innovative products, such as the Endotoxin Activity Assay and Polymyxin B-Hemoperfusion device, are designed to address significant healthcare challenges associated with septic shock. The recent increase in quarterly revenue reflects a growing market demand for these solutions, while the company's international expansion efforts further enhance its growth potential. Financially, the company has shown resilience, with a notable improvement in net income in the latest quarter. The current cash position provides a buffer for ongoing operations and potential investments in research and development. As the healthcare landscape continues to evolve, Spectral Medical Inc. remains committed to advancing its product offerings, which may lead to increased market share and improved patient outcomes.
AI Generated • Aug 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

29

CEO

Chris Seto, MBA

Website

www.spectraldx.com

Headquarters

Toronto, ON M9C 1C2, CA

EDTXF Financials

Key Financial Metrics (TTM)

Gross Margin

-94.78%

Operating Margin

-431.14%

Net Income Margin

-1391.98%

Return on Equity

51.23%

Return on Capital

N/A

Return on Assets

-1121.00%

Earnings Yield

-9.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$267.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

293.93M

Volume

7.38K

Avg. Volume

8.40K

Financials (TTM)

Gross Profit

-CA$2.44M

Operating Income

-CA$11.08M

EBITDA

-CA$32.39M

Operating Cash Flow

-CA$10.92M

Capital Expenditure

-CA$28.00K

Free Cash Flow

-CA$10.95M

Cash & ST Invst.

CA$803.00K

Total Debt

CA$25.68M

Spectral Medical Performance Analysis

Spectral Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 1,280,482-19.6%
20232023-12-31CAD 1,183,978-7.5%
20242024-12-31CAD 1,668,66040.9%
20252025-12-31CAD 1,747,6704.7%
Spectral Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-17.0%
Q42025-12-31-43.5%
Q12026-03-31134.0%
Q22026-06-30-30.5%
Spectral Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.0315.5%
20232023-12-31CAD -0.0429.9%
20242024-12-31CAD -0.04-4.1%
20252025-12-31CAD -0.12197.0%
Spectral Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-1517.6%
Q42025-12-3191.2%
Q12026-03-31-3.1%
Q22026-06-30111.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$621.00K

-23.6%

Gross Profit

CA$275.00K

-47.3%

Gross Margin

44.28%

N/A

Market Cap

$267.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.23M

N/A

Employees

29

N/A

Net Income

CA$331.00K

+117.1%

EBITDA

CA$2.12M

+402.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$803.00K

-74.1%

Total Debt

CA$25.68M

+46.0%

Accounts Receivable

CA$427.00K

+39.5%

Inventory

CA$369.00K

+51.2%

Long Term Debt

CA$6.71M

+162.0%

Short Term Debt

CA$18.97M

+26.2%

Return on Assets

-11.21%

N/A

Return on Invested Capital

18.76%

N/A

Free Cash Flow

-CA$2.52M

+7.2%

Operating Cash Flow

-CA$2.52M

+7.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CMVLFCellectis S.A.
$3.47+12.66%
DMTRF3-D Matrix, Ltd.
$2.50+0.00%
COGZFCogstate Limited
$2.11+0.00%
ABTIAlterola Biotech, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ACVAACV Auctions
$10.42+0.44%
TNONTenon Medical
$10.21+0.93%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$19.61+0.06%
ORCLOracle
$154.02+0.01%

Questions About EDTXF

What is the current price of Spectral Medical?

Spectral Medical is trading at $0.91 per share.

What is the 52-week range for Spectral Medical?

Over the past 52 weeks, Spectral Medical has traded between $0.81 and $1.24.

How much debt does Spectral Medical have?

As of the most recent reporting period, Spectral Medical reported total debt of CA$17.43M.

How much cash does Spectral Medical have on hand?

Spectral Medical reported CA$565.99K in cash and cash equivalents in its most recent financial results.

What is Spectral Medical’s dividend yield?

Spectral Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services